| MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease M Eslam, AJ Sanyal, J George, A Sanyal, B Neuschwander-Tetri, ... Gastroenterology 158 (7), 1999-2014. e1, 2020 | 2918 | 2020 |
| Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial BA Neuschwander-Tetri, R Loomba, AJ Sanyal, JE Lavine, ML Van Natta, ... The Lancet 385 (9972), 956-965, 2015 | 2511 | 2015 |
| A multisociety Delphi consensus statement on new fatty liver disease nomenclature ME Rinella, JV Lazarus, V Ratziu, SM Francque, AJ Sanyal, F Kanwal, ... Hepatology 78 (6), 1966-1986, 2023 | 2454 | 2023 |
| Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease C Estes, H Razavi, R Loomba, Z Younossi, AJ Sanyal Hepatology 67 (1), 123-133, 2018 | 2293 | 2018 |
| The global NAFLD epidemic R Loomba, AJ Sanyal Nature reviews Gastroenterology & hepatology 10 (11), 686-690, 2013 | 2080 | 2013 |
| Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies S Singh, AM Allen, Z Wang, LJ Prokop, MH Murad, R Loomba Clinical gastroenterology and hepatology 13 (4), 643-654. e9, 2015 | 1872 | 2015 |
| Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta‐analysis PS Dulai, S Singh, J Patel, M Soni, LJ Prokop, Z Younossi, G Sebastiani, ... Hepatology 65 (5), 1557-1565, 2017 | 1842 | 2017 |
| Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030 C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ... Journal of hepatology 69 (4), 896-904, 2018 | 1774 | 2018 |
| Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention DQ Huang, HB El-Serag, R Loomba Nature reviews Gastroenterology & hepatology 18 (4), 223-238, 2021 | 1407 | 2021 |
| Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with … P Zhang, L Zhu, J Cai, F Lei, JJ Qin, J Xie, YM Liu, YC Zhao, X Huang, ... Circulation research 126 (12), 1671-1681, 2020 | 1360 | 2020 |
| Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease L Castera, M Friedrich-Rust, R Loomba Gastroenterology 156 (5), 1264-1281. e4, 2019 | 1327 | 2019 |
| Mechanisms and disease consequences of nonalcoholic fatty liver disease R Loomba, SL Friedman, GI Shulman Cell 184 (10), 2537-2564, 2021 | 1235 | 2021 |
| The gut–liver axis and the intersection with the microbiome A Tripathi, J Debelius, DA Brenner, M Karin, R Loomba, B Schnabl, ... Nature reviews Gastroenterology & hepatology 15 (7), 397-411, 2018 | 1199 | 2018 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1165 | 2019 |
| AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease ME Rinella, BA Neuschwander-Tetri, MS Siddiqui, MF Abdelmalek, ... Hepatology 77 (5), 1797-1835, 2023 | 989 | 2023 |
| Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease R Loomba, V Seguritan, W Li, T Long, N Klitgord, A Bhatt, PS Dulai, ... Cell metabolism 25 (5), 1054-1062. e5, 2017 | 975 | 2017 |
| Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis R Khera, MH Murad, AK Chandar, PS Dulai, Z Wang, LJ Prokop, ... Jama 315 (22), 2424-2434, 2016 | 962 | 2016 |
| Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty … CC Park, P Nguyen, C Hernandez, R Bettencourt, K Ramirez, L Fortney, ... Gastroenterology 152 (3), 598-607. e2, 2017 | 737 | 2017 |
| A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis SL Friedman, V Ratziu, SA Harrison, MF Abdelmalek, GP Aithal, ... Hepatology 67 (5), 1754-1767, 2018 | 734 | 2018 |
| Prospective study of outcomes in adults with nonalcoholic fatty liver disease AJ Sanyal, ML Van Natta, J Clark, BA Neuschwander-Tetri, AM Diehl, ... New England Journal of Medicine 385 (17), 1559-1569, 2021 | 697 | 2021 |